Therefore, with a promising application in NSCLC, B7H3-based drugs, such as oncolytic viruses, B7H3 blockades, ADCs, have shown pretty good antitumor efficacy accompanied by an increased number of CD8+ TILs, M1-polarized macrophages and immune cell reactivation [26, 43, 44]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.